Attomarker is a multiplex blood-testing technology company established at the University of Exeter. The Smiths Detection team worked alongside Attomarker on the design and performance of a COVID-19 antibody testing device that could represent an evolution in rapid and precise COVID-19 antibody testing. The Medicines and Healthcare Products Regulatory Agency (MHRA) approved Attomarker’s Triple Antibody Test for NHS use in the UK.
Attomarker’s Triple Antibody Test device is a portable, desktop, antibody-testing device designed to provide laboratory-standard results in any environment. It delivers rapid, accurate, quantitative results in just seven minutes – compared with up to 72 hours for tests that require to be sent away for laboratory analysis.
The result of a trial at St Thomas’ Hospital in London shows that the Attomarker Triple Antibody Test delivers a sensitivity of up to 96% in detecting COVID-19 antibodies, including in patients who have previously presented false negatives. This is a significant improvement on recently announced tests, which range between 83.9% - 93.9% - though not with real world patients.
The Smiths Detection team was able to take the current designs of the existing product and make enhancements that contributed not only to its improved performance and robustness, but also improvements to supply chain, manufacturing and quality enabling the team to ramp up volume according to demand.
Read the full press release here